Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GSK unveils cost-cutting plan

GlaxoSmithKline (LSE:GSK; GSK) announced a cost-savings plan that seeks to offset some of the effect of generic competition and declining sales

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE